Henlius Reports First Patients Dosing in P-I Study of HLX14 (denosumab, biosimilar)

Shots:

• The first patient has been dosed in a P-I study of HLX14, conducted in 2 parts, Part 1 is a pilot study assessing PK/PD, safety, tolerability & immunogenicity of HLX14 vs EU-sourced denosumab (SC) in healthy male volunteers
• Part 2 is a four-arm study assessing the bioequivalence of HLX14 vs US-, EU-, CN-sourced denosumab. The study also evaluates PD, safety, tolerability, and immunogenicity between HLX14 and the reference drug
• Results from the P-I study will provide reference for the dosing scheme in the clinical studies of HLX14

Click here ­to­ read full press release/ article | Ref: Henlius | Image: BioSpectrum Asia